Correction: Quality Tolerance Limits' Place in the Quality Management System and Link to the Statistical Trial Design: Case Studies and Recommendations from Early Adopters
Ther Innov Regul Sci
.
2023 Sep;57(5):1121.
doi: 10.1007/s43441-023-00546-w.
Authors
Marion Wolfs
1
,
Łukasz Bojarski
2
,
Steve Young
3
,
Lynne Cesario
4
,
Marcin Makowski
5
,
Linda B Sullivan
6
Affiliations
1
Integrated Data Analytics and Reporting, Janssen Research and Development, Graaf Engelbertlaan 75, 4837DS, Breda, Netherlands. Mwolfs1@its.jnj.com.
2
Development Operations, AstraZeneca R&D BioPharmaceuticals, ul. Postepu 14, 02-675, Warsaw, Poland.
3
CluePoints Inc, King of Prussia, PA, USA.
4
Pfizer R&D, New York, NY, USA.
5
Data Strategy and Management, GlaxoSmithKline GmbH & Co. KG, Prinzregentenpl. 9, 81675, Munich, Germany.
6
Metrics & Performance Management, WCG, Indianapolis, IN, USA.
PMID:
37332050
PMCID:
PMC10400666
DOI:
10.1007/s43441-023-00546-w
No abstract available
Publication types
Published Erratum